IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study
◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline
◦ associated with improved BASFI, fatigue, SF36
Ramiro S Abs1009 t.co/GiCqg7W9IR #ACR22 @RheumNow
Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial - ACR Meeting Abstracts
◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline
◦ associated with improved BASFI, fatigue, SF36
Ramiro S Abs1009 t.co/GiCqg7W9IR #ACR22 @RheumNow
